Australia · Delayed Price · Currency is AUD Arovella Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A differentiated off-the-shelf CAR-iNKT cell therapy platform is advancing to first-in-human trials for blood cancers, with expansion plans for solid tumors and autoimmune diseases. The approach offers cost, speed, and safety advantages, with key milestones and early clinical data expected in the next 6–12 months.
Fiscal Year 2025
-
The meeting highlighted strong financial positioning, major progress toward clinical trials for lead asset ALA-101, and strategic pipeline expansion into solid tumors. Leadership transitions and new hires were announced, with confidence in overcoming sector challenges and regulatory milestones.
-
The meeting addressed two resolutions related to the March 2025 placement, with voting conducted by poll and results to be released on ASX. Shareholders' questions focused on webcast access and meeting formats, with future meetings planned as hybrid or in-person.
-
Lead iNKT cell therapy ALA-101 is on track for phase I trials in 2025, supported by a strong cash position and recent capital raise. Expansion into solid tumors with CLDN18.2 and IL-12-TM armoring is progressing, with key preclinical and manufacturing milestones achieved.